Glomerulosclerosis Clinical Trials
A listing of Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 18 clinical trials
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
- 83 views
- 20 Jul, 2021
- 45 locations
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
- 226 views
- 01 Aug, 2021
- 104 locations
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
- 33 views
- 27 Jan, 2021
- 1 location
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post
- 36 views
- 07 May, 2021
- 8 locations
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.
- 83 views
- 25 Jan, 2021
- 1 location
Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER LA-15 System
associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well
- 1 views
- 05 May, 2021
- 10 locations
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- 12 views
- 26 Jan, 2021
- 4 locations
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy Focal Segmental Glomerulosclerosis and Treatment-Resistant Minimal Change Disease
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and
- 69 views
- 01 Jul, 2021
- 50 locations
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
change disease or focal segmental glomerulosclerosis unresponsive to 8 weeks of high dose prednisone . patients either receive 2 doses of Rituximab 375 mg/m2 iv at time 0 and 14 days with
- 52 views
- 22 Jan, 2021
- 1 location
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- 0 views
- 17 Jul, 2021
- 18 locations
- 1
- 2